@article{Cambridge_Institute_of_Therapeutic_Immunology_and_Infectious_Disease-National_Institute_of_Health_Research_CITIID-NIHR_Covid_BioResource_Collaboration-2022_112161,
title = {Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19},
author = {Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) Covid BioResource Collaboration and Wang, Jun and Kotagiri, P. and Lyons, P. and Al-Lamki, R. and Mescia, F. and Bergamaschi, L. and Turner, L. and Morgan, M. and Calero-Nieto, F. and Bach, K. and Mende, N. and Wilson, N. and Watts, E. and Maxwell, P. and Chinnery, P. and Kingston, N. and Papadia, S. and Stirrups, K. and Walker, N. and Gupta, R. and Menon, D. and Allinson, K. and Aitken, S. and Toshner, M. and Weekes, M. and Nathan, J. and Walmsley, S. and Ouwehand, W. and Kasanicki, M. and Göttgens, B. and Marioni, J. and Smith, K. and Pober, J. and Bradley, J.},
month = {feb},
year = {2022},
abstract = {Clotting Factor V (FV) is primarily synthesized in the liver and when cleaved by thrombin forms pro-coagulant Factor Va (FVa). Using whole blood RNAseq and scRNAseq of peripheral blood mononuclear cells, we find that FV mRNA is expressed in leukocytes, and identify neutrophils, monocytes, and T regulatory cells as sources of increased FV in hospitalized patients with COVID-19. Proteomic analysis confirms increased FV in circulating neutrophils in severe COVID-19, and immunofluorescence microscopy identifies FV in lung-infiltrating leukocytes in COVID-19 lung disease. Increased leukocyte FV expression in severe disease correlates with T-cell lymphopenia. Both plasma-derived and a cleavage resistant recombinant FV, but not thrombin cleaved FVa, suppress T-cell proliferationin vitro. Anticoagulants that reduce FV conversion to FVa, including heparin, may have the unintended consequence of suppressing the adaptive immune system.},
volume = {25},
issue = {3},
journal = {iScience},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.isci.2022.103971},
}
